You are currently browsing the category archive for the ‘Directors buying’ category.

I wondered why Rob de Groot, EVP at Reckitt Benckiser (RB., 2724p) had been buying so aggressively (GBP 3m+ in last two weeks) whereas Bart Becht has been selling.

If you look through the Annual Report, you’ll see that it is group policy for senior management to hold shares, thereby aligning themselves with shareholders. EVPs have to own 200,000 shares before they get any options or performance awards. 200,000 shares is a lot of $$, over GBP 5m at current prices. De Groot was appointed to EVP position in July 2008.

Just imagine how the attitude to risk would have changed if you had had to do that at Lehman, Bear or Merrill !!

Bart Becht has been selling down his exercised options. He exercised 600,000 options in June, and has sold 200,000 shares since. I’m sure he has more to go.

Neither of these sets of transactions can be used as signal on which to predict future share price performance.

Axis Shield (ASD, 307p) (website) is an old favourite of mine. I met the company, and at the same time noticed directors buying in Spring 2005 at prices almost double where they were a year earlier. The stock then continued to perform, moving up 50% within months.

Now I see that Erik Hornnaess, a non exec director but previously Chairman of Axis before their merger in 1999, has been buying shares which have outperformed the market by 40% so far this year.

Between September 3rd and 15th, Hornnaess has bought 20,000 shares at 320p, taking his holding to 125,961 shares. Four of his colleagues had earlier this year (January to April) also bought shares, all around the 270p level. They are Keen (non exec Chairman), McAndrew (previously non exec Chairman), Hermansen (CFO) and Gilham (CEO).

Signal strength: MEDIUM

This is a small cap company with a market cap of only GBP 150m. Be patient and you will be rewarded.

See also April 8th comment- closing positive view with 79% relative return.

Almost every time I’ve looked at directors dealings over the last few weeks I spot a small resources company. This time it is Heritage Oil (HOIL, 253p).

Heritage initiated a London listing in April this year, trading around the 300p mark, before heading up to a high of 350p in June and a low of 190p in August.

Non exec directors Michael Hibberd and Gregory Turnbull each bought 50,000 shares on 5th September at 215p and 212p respectively.

Hibberd followed this up with a further purchase of 75,000 shares at 182p on September 16th, taking his holding to 125,000 shares (plus options on 1.15m shares). Turnbull now holds 350,000 shares (and options on 600,000).

Good news? Each investing GBP 100k-250k. Two directors. decent percentage of existing (Hibberd new position and Turnbull 17%). But I’d like to see more directors buying for this to get a ‘STRONG signal’ rating.

Signal strength: MEDIUM

New World Resources (NWR, 900p) is a Czech and Central European coal miner, producing coking coal and thermal coal.

NWR has a secondary listing in London, and caught my attention last week when two directors bought GBP 30k-40k each at above 1050p. They were followed this week by three more, investing GBP 35k to GBP 250k each, a not inconsiderable sum, at prices between 718p and 940p.

The stock has halved since they produced interim results at the end of August (link to company website). I shalln’t [how do you spell this word] attempt to analyse the results, but the main two points were a huge jump in operating cash flow (172%) due to prices, and a big jump in costs (15% underlying).

Conclusion: Five directors buying (2 execs, three non execs), good size (GBP 35k to 250k), and a significant increase in shareholding (25% to 100% of existing holding) warrant a STRONG signal.

Risk factors include: secondary listing in London, relatively recent IPO (May).

For the official announcements of directors dealings in NWR go to the London Stock Exchange ‘Market News’ website, and type ‘NWR’ in the ‘name/code’ box.

I want to revisit Shire (SHP, 911p).

In February David Mott, a non exec with a great pedigree, initiated a position in Shire by investing GBP 150k, saying ‘Shire is one of the most interesting companies in the industry with an impressive recent track record of launches and an equally exciting pipeline’ (see ‘David Mott- puts his money where his mouth is‘).

Last Thursday, Mott committed almost the same amount of cash again, doubling his holding to the equivalent of 30,000 ordinary shares in Shire, by buying 5,000 ADS at $48 (equivalent to buying 15,000 ords at 910p).

I also find other recent purchases:

August 6th Graham Hetherington, CFO, buys 4000 shares at 896p taking him to 56,000 shares.

August 5th Matthew Emmens. Non exec Chairman,  exercises options on almost 40,000 shares at an average price of around 430p. He would normally need to sell roughly 40% of these shares to pay for the tax liable, but is not doing so, so I consider this transaction to be a net investment by Emmens.

August 1st Michael Rosenblatt, Non exec,  bought 1155 shares at 800p

June 13th Aungus Russell, CEO, bought 6000 shares at 804p

If I then look back further to see if directors have historically bought and sold at the ‘right’ times, and I find the following:

I see directors were buyers at 868p to 888p level in September 2006.

Then from November 2006 to September 2007 they were net sellers (exercised options and sold almost all the shares) in range of 1056p to 1270p (shares peaked at 1310p in August 2007)

And now they are buyers again, as from February this year, in range of 804p to 998p (shares troughed at 745p on July 16th).

With the observation of ongoing buying activity in decent $$ amounts, as well as having several directors buying over a short period, I believe the ‘signal’ given by directors dealing activity in Shire Ltd should move from WEAK to STRONG.

‘Founded over twenty years ago, System C has built up expertise in nearly every area of healthcare IT and medical software interfacing.  System C works right across the healthcare sector, and with all types of clinical information systems, including patient-based IT systems.’  (Source- System C Healthcare website)

I was drawn to this stock by a flurry of director activity, where three directors invested [a small amount of money] around GBP 16k-20k each (September 10th, Ian Denley CEO, Markus Bolton Strategy and Sales, and Andrew Coll CFO- source London Stock Exchange).

Whilst not significant in $$ size or % increase in holdings, having the CEO, CFO and Head of Sales and Strategy all buying shares 50% more expensive than last week certainly got me thinking.

At the end of May (then 28p) System C Healthcare (SYS,now 42p) announced they would beat market expectations. They clearly have, given the share price move.

These are the first directors share purchases since System C was listed on AIM at 54p in June 2005.

Have a look at the results, especially the high level of cash generation.

I’d have this as a ‘STRONG signal’ if the directors purchases were more substantial.

Until then System C’s director dealing activity justifies a  ‘MEDIUM strength signal’

I’ve not a lot to say about the Directors of Barclays (BARC, 335p) buying in last weeks placement at 282p, except to say that

1. I can imagine that there must have been a lot of internal pressure on the directors of Barclays to subscribe for shares in the placement, and given that pressure, an increase in their personal holdings of Barclays shares of between 15% and 23% doesn’t seem to me particularly, how shall I say this, convincing.

2. I looked back through recent directors trades, and see in particular that Bob Diamond in March 2008, having exercised and been delivered shares in various incentive and award schemes, sold 974,000 shares at prices of 454p (4/3) and 461p (12/3) to ‘satisfy withholding liabilities’ *. I find it an intriguing coincidence then that he buys [back] almost the same amount, 1,025,000 shares at 282p last week.

* ‘satisfy withholding liabilities’ = pay tax. This is normal routine behaviour when share options are exercised or released to directors.

On the 29th of July we saw the Chairman of Marks and Spencer David Michels (MKS, 257p) add to his holding by buying 47500 shares at 248.75p.

Is this significant ? NO.

1. This is a relatively small amount of money (£118,000)

2. No other directors are buying shares at the moment. The last significant purchase was in January by Stuart Rose, who invested £1m at 411p.

I noted on Match 31st that I had seen significant buying by the CEO, CFO and Chairman of Misys (MSY, 172p). (link to note of 31/3 here). Misys are up more than 35% relative to the FTSE250 index since March 31st, fuelled recently by some outstanding results and a positive outlook (July 24th comment by Reuters here).

Yesterday we saw Dominic Cadbury, the Chairman of Misys, reinforcing his beliefs by investing £617,000, a sizable amount in anybodys money. He bought 380,000 shares at 162.5p, to more than double his holding to 655,000 shares.

It wouldn’t surprise me to see other directors follow suit shortly.

This move strongly reinforces my comments of March 31st.

PureCircle (PURE 205p) manufacture sugar substitutes from a plant called Stevia.

I was drawn to the company by the disclosure on July 1st ( see http://www.purecircle.com) that a non exec Olivier Maes, had spent £162,000 buying 80,000 shares in PureCircle at 203p.

PureCircle subsequently announced a date for their Interim Results, September 17th.

PureCircle were listed on Aim in December at 170p.

I think £162,000 is a large initial position to take for a non exec, and look forward to seeing what news the Interim results bring.

Add to Technorati Favorites

Prefer to get emails? Click here

RSS Find us on twitter.com/directorsdeals

  • An error has occurred; the feed is probably down. Try again later.

twitter

March 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031